Fibrosarcoma

Fibrosarcoma is a malignant mesenchymal neoplasm arising from fibroblasts, characterized by the production of collagen fibers. In the oral cavity, it typically presents as a firm, infiltrative, and locally aggressive mass involving the gingiva, hard palate, tongue, or buccal mucosa. It is the third most common oral malignancy in dogs and the second most common in cats. Histologically, it is composed of spindle-shaped cells arranged in interlacing bundles (herringbone pattern) with variable mitotic activity and collagen deposition. Oral fibrosarcomas are often high-grade, with a propensity for local recurrence and a moderate to high metastatic rate, particularly to regional lymph nodes and lungs. The biological behavior can vary, with some tumors being low-grade and slowly progressive, while others are highly aggressive. Complete surgical excision is the treatment of choice, but achieving clean margins is often challenging due to the infiltrative nature of the tumor. Adjunctive therapies such as radiation therapy and chemotherapy may be employed to improve local control and survival.

The exact etiology of oral fibrosarcoma is not fully understood, but several factors have been implicated. In cats, a strong association has been established between fibrosarcoma and chronic inflammation at injection sites, particularly with vaccines (feline vaccine-associated sarcoma). This is believed to be triggered by the local inflammatory response to vaccine adjuvants, leading to malignant transformation of fibroblasts. In dogs, no clear etiological agent has been identified, but genetic mutations, such as alterations in the p53 tumor suppressor gene and overexpression of growth factors, may play a role. Chronic trauma or irritation has been suggested as a potential contributing factor, though evidence is limited. Additionally, retroviral infections, such as feline sarcoma virus (FeSV), can cause multicentric fibrosarcomas in young cats, though this is rare. Environmental factors, such as exposure to certain chemicals or radiation, have not been conclusively linked to oral fibrosarcoma.

Oral fibrosarcoma occurs predominantly in dogs and cats, with a higher incidence in certain breeds. In dogs, large breeds such as Golden Retrievers, Labrador Retrievers, Boxers, and Rottweilers are overrepresented. The average age of onset is around 7 to 9 years, with no significant sex predilection. In cats, the disease is more common in middle-aged to older individuals, with a median age of 10 years. Vaccine-associated fibrosarcomas typically occur at a younger age, often within 2 to 3 years after vaccination. The tumor accounts for approximately 10-20% of all oral tumors in dogs and 20-30% in cats. It is more frequently diagnosed in the oral cavity than in other sites, with the gingiva and hard palate being the most common locations. There is no known geographic or seasonal variation, but the incidence of vaccine-associated sarcomas has decreased with the use of newer, non-adjuvanted vaccines.

Fibrosarcoma arises from fibroblasts in the connective tissue of the oral mucosa. The neoplastic cells proliferate locally, forming a mass that invades surrounding tissues, including bone, muscle, and neurovascular structures. The tumor is characterized by an infiltrative growth pattern, with finger-like projections extending beyond the palpable mass, making complete surgical excision difficult. Histologically, the tumor is composed of spindle cells with variable nuclear atypia and mitotic activity. High-grade tumors exhibit increased cellularity, pleomorphism, and necrosis. The tumor induces a desmoplastic response, with abundant collagen production. Local invasion can lead to bone lysis, tooth loss, and functional impairment. Metastasis occurs primarily via the hematogenous route, with the lungs being the most common site of distant spread. Lymphatic invasion is less common but can lead to regional lymph node metastasis. The tumor may also secrete growth factors and cytokines that promote angiogenesis and local immunosuppression, facilitating tumor progression.

Several factors predispose to the development of oral fibrosarcoma. In cats, the most significant risk factor is prior vaccination, particularly with adjuvanted vaccines, leading to vaccine-associated sarcoma. Chronic inflammation at injection sites, as well as trauma or foreign body reactions, may also increase the risk. In dogs, breed predisposition suggests a genetic component, with certain breeds having a higher incidence. Age is a risk factor, as the tumor is more common in middle-aged to older animals. Immunosuppression, whether due to concurrent disease or medication, may increase susceptibility. Additionally, exposure to environmental carcinogens, such as tobacco smoke or certain chemicals, has been hypothesized but not proven. Poor oral hygiene and chronic periodontal disease may contribute to local inflammation, though a direct causal link has not been established.

Clinical signs of oral fibrosarcoma depend on the size and location of the tumor. Early signs may be subtle, including mild halitosis, excessive drooling, or a slight change in eating habits. As the tumor grows, owners may notice a visible mass in the oral cavity, difficulty eating (dysphagia), weight loss, and oral bleeding. The tumor may cause loosening or loss of teeth, and in advanced cases, facial swelling or deformity may be evident. On physical examination, the mass is typically firm, fixed to underlying tissues, and may be ulcerated or necrotic. Palpation may elicit pain. Regional lymph nodes may be enlarged if metastasis has occurred. In cats with vaccine-associated sarcoma, a mass may be palpable at the injection site, often in the interscapular region, but oral fibrosarcomas can also occur. Systemic signs such as lethargy and anorexia are uncommon unless the tumor is advanced or has metastasized.

Differential diagnoses for oral fibrosarcoma include other oral tumors and non-neoplastic conditions. Key differentials include: 1) Oral squamous cell carcinoma (SCC) - the most common oral malignancy in cats and second in dogs; it often presents as a proliferative or ulcerative mass, with a predilection for the tongue and tonsils; histopathology is definitive. 2) Malignant melanoma - common in dogs, often pigmented, but can be amelanotic; it is highly metastatic; immunohistochemistry (Melan-A, PNL2) helps differentiate. 3) Osteosarcoma - arises from bone, causing lytic and proliferative changes on radiographs; histopathology shows osteoid production. 4) Chondrosarcoma - cartilaginous origin, rare in the oral cavity. 5) Peripheral odontogenic fibroma - a benign tumor of odontogenic epithelium, slow-growing, and non-invasive. 6) Epulis (fibromatous, ossifying, acanthomatous) - benign gingival proliferations; acanthomatous epulis can be locally invasive but does not metastasize. 7) Granulomatous inflammation (e.g., fungal, foreign body) - may mimic a mass; biopsy and culture are needed. 8) Eosinophilic granuloma complex in cats - presents as ulcerative or proliferative lesions, often on the lips or tongue; responds to immunosuppressive therapy. 9) Fibrous hyperplasia - benign proliferation of fibrous tissue, often due to chronic irritation. 10) Ameloblastoma - a benign odontogenic tumor, locally invasive but non-metastatic. Definitive diagnosis requires histopathology, often with immunohistochemistry.

The diagnostic workup for oral fibrosarcoma should follow a systematic approach. 1) Complete history and physical examination, including thorough oral examination under sedation or anesthesia, with palpation of the mass and regional lymph nodes. 2) Fine-needle aspiration (FNA) of the mass and any enlarged lymph nodes for cytology. Cytology may reveal spindle cells, but it is often non-diagnostic; a biopsy is required for definitive diagnosis. 3) Incisional or excisional biopsy for histopathology. A wedge biopsy is preferred to obtain a representative sample, avoiding necrotic areas. 4) Staging: Thoracic radiographs (three views) to evaluate for pulmonary metastasis. Abdominal ultrasound may be considered if there is suspicion of abdominal metastasis, though it is rare. 5) Advanced imaging: CT or MRI of the head is highly recommended to assess the extent of the tumor, bone invasion, and involvement of adjacent structures. CT is particularly useful for surgical planning. 6) Lymph node evaluation: FNA or biopsy of regional lymph nodes (mandibular, retropharyngeal) to assess for metastasis. 7) Histopathological grading: The tumor is graded based on mitotic index, cellular pleomorphism, and necrosis. High-grade tumors have a worse prognosis. 8) Immunohistochemistry: May be used to differentiate fibrosarcoma from other spindle cell tumors (e.g., vimentin positive, cytokeratin negative). 9) Baseline blood work (CBC, biochemistry, urinalysis) to assess overall health and anesthetic risk.

Laboratory findings in oral fibrosarcoma are often non-specific. Complete blood count (CBC) may reveal mild anemia if there is chronic bleeding from the tumor, or leukocytosis due to secondary infection. Serum biochemistry may show elevated globulins due to chronic inflammation, but liver and kidney parameters are typically within normal limits. Urinalysis is usually unremarkable. There are no specific tumor biomarkers for fibrosarcoma. In cats, testing for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) may be considered, especially in young cats with multicentric fibrosarcoma, though the association is weak. Baseline blood work is essential for anesthetic planning and to rule out concurrent diseases. If radiation therapy is planned, a complete blood count and biochemistry profile are necessary to assess bone marrow and organ function.

Imaging plays a crucial role in the evaluation of oral fibrosarcoma. Thoracic radiographs (three views) are essential to detect pulmonary metastasis, which appears as well-defined nodular opacities. However, early metastasis may not be visible on radiographs; CT is more sensitive. For the oral cavity, dental radiographs can reveal bone lysis, tooth root resorption, or periosteal reaction. However, CT is the imaging modality of choice for assessing the extent of the tumor, including bone invasion, soft tissue involvement, and regional lymph node enlargement. CT provides detailed three-dimensional information that is critical for surgical planning and radiation therapy planning. MRI offers superior soft tissue contrast and is particularly useful for evaluating intracranial extension or involvement of the tongue base. Ultrasonography is not typically used for oral masses but may be used to evaluate cervical lymph nodes. In cases of suspected metastasis, abdominal ultrasound may be performed, though it is rarely indicated.

Cytology from fine-needle aspiration of oral fibrosarcoma often yields low cellularity with spindle-shaped cells, which may be arranged in clusters or individually. The cells may show mild to moderate atypia, but cytology is often non-diagnostic and cannot reliably differentiate fibrosarcoma from other mesenchymal tumors. Histopathology is the gold standard for diagnosis. On histopathological examination, the tumor is composed of interlacing bundles of spindle cells with variable collagen production. The cells have elongated nuclei, prominent nucleoli, and variable mitotic activity. High-grade tumors exhibit increased cellularity, pleomorphism, and areas of necrosis. The tumor is infiltrative, with neoplastic cells extending into surrounding tissues. Special stains, such as Masson's trichrome, can highlight collagen. Immunohistochemistry is often used to confirm the diagnosis: fibrosarcomas are typically positive for vimentin and negative for cytokeratin, S100, and Melan-A. This helps differentiate from carcinomas, melanomas, and other sarcomas. Histopathological grading (based on mitotic index, necrosis, and differentiation) is important for prognosis.

Treatment of oral fibrosarcoma is multimodal and depends on the tumor stage and grade. The primary treatment is surgical excision with wide margins (at least 2 cm) to achieve clean margins. However, due to the infiltrative nature of the tumor, complete excision is often difficult, especially in the oral cavity. If clean margins are not achieved, adjuvant radiation therapy is recommended. Radiation therapy can be used as a primary treatment for non-resectable tumors or as an adjunct after surgery. It provides good local control, with reported response rates of 60-80%. Stereotactic radiation therapy (SRS/SRT) may be used for small tumors. Chemotherapy is generally not highly effective for fibrosarcoma, but drugs such as doxorubicin, ifosfamide, or mitoxantrone may be used in cases of metastasis or high-grade tumors. Metronomic chemotherapy (e.g., low-dose cyclophosphamide and piroxicam) has been used to inhibit angiogenesis. Palliative care includes pain management (NSAIDs, opioids), nutritional support (feeding tube if dysphagia), and antibiotics for secondary infections. In cats with vaccine-associated sarcomas, aggressive surgical excision with wide margins is crucial, and radiation therapy is often recommended. Immunotherapy, such as tyrosine kinase inhibitors (e.g., toceranib), has shown some efficacy in treating sarcomas, though data in oral fibrosarcoma is limited.

The prognosis for oral fibrosarcoma is guarded to poor, depending on several factors. Tumor grade is a significant prognostic indicator: low-grade tumors have a better prognosis, with a median survival time (MST) of 2-3 years, while high-grade tumors have an MST of 6-12 months. The ability to achieve clean surgical margins is critical; tumors with clean margins have a lower recurrence rate and longer survival. Tumor size and location also influence prognosis; tumors in the rostral oral cavity are more amenable to complete excision than those in the caudal oral cavity. Metastasis at the time of diagnosis is a poor prognostic indicator, with a median survival of less than 6 months. In cats, vaccine-associated fibrosarcomas have a high recurrence rate (up to 70%) if not aggressively treated. Overall, the metastatic rate for oral fibrosarcoma is reported to be 20-40%, with the lungs being the most common site. Regular monitoring for recurrence and metastasis is essential.

Post-treatment follow-up for oral fibrosarcoma should be rigorous. Patients should be re-examined every 1-3 months for the first year, then every 3-6 months thereafter. Each examination should include a thorough oral examination and palpation of regional lymph nodes. Thoracic radiographs should be repeated every 3-6 months to monitor for pulmonary metastasis. If radiation therapy was administered, follow-up imaging (CT or MRI) may be performed to assess response and detect recurrence. Blood work (CBC, biochemistry) should be monitored if chemotherapy is used, to assess for myelosuppression or organ toxicity. Owners should be educated on signs of recurrence, such as a new mass, difficulty eating, or oral bleeding. In cases of incomplete excision, early re-excision or radiation therapy should be considered. Long-term management may include pain management and nutritional support. For cats, vaccination protocols should be adjusted to minimize the risk of vaccine-associated sarcomas, using non-adjuvanted vaccines and alternating injection sites.

Pearls: 1) Always perform a biopsy of any oral mass before definitive surgery, as the treatment plan may change based on histology. 2) Use advanced imaging (CT) for surgical planning to assess the extent of the tumor and bone invasion. 3) Aim for wide surgical margins (at least 2 cm) to reduce the risk of recurrence. 4) Consider radiation therapy for incompletely excised tumors or non-resectable masses. 5) In cats, be aware of vaccine-associated sarcomas and recommend appropriate vaccination protocols. 6) Monitor for metastasis with regular thoracic radiographs. Pitfalls: 1) Relying solely on cytology for diagnosis, as it is often non-diagnostic. 2) Underestimating the tumor extent due to lack of imaging, leading to incomplete excision. 3) Delaying treatment, as fibrosarcomas can grow rapidly. 4) Neglecting to evaluate regional lymph nodes for metastasis. 5) Using NSAIDs without considering renal or gastrointestinal contraindications. 6) Failing to provide adequate pain management, especially in advanced cases.

Chemotherapy protocols for oral fibrosarcoma are not standardized, but the following agents may be used based on Plumb's Veterinary Drug Handbook. Doxorubicin: Dogs: 30 mg/m² IV every 3 weeks; Cats: 1 mg/kg IV every 3 weeks (or 20-25 mg/m²). It is a vesicant; ensure proper IV administration. Monitor for cardiotoxicity (cumulative dose limit 180-240 mg/m² in dogs) and myelosuppression. Ifosfamide: Dogs: 375 mg/m² IV every 3 weeks, with mesna (20% of ifosfamide dose) to prevent hemorrhagic cystitis. Cats: 300 mg/m² IV every 3 weeks. Mitoxantrone: Dogs: 5-6 mg/m² IV every 3 weeks; Cats: 6.5 mg/m² IV every 3 weeks. Metronomic chemotherapy: Cyclophosphamide: 10 mg/m² PO every 24 hours, and Piroxicam: 0.3 mg/kg PO every 24 hours (dogs) or 1 mg/cat PO every 48 hours (cats). This protocol is used for its anti-angiogenic effects. Toceranib (Palladia): Dogs: 2.75-3.25 mg/kg PO every 48 hours; monitor for gastrointestinal and hematologic side effects. It is a tyrosine kinase inhibitor with activity against some sarcomas. For pain management, NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) can be used, but caution with renal disease. Opioids like tramadol (2-5 mg/kg PO q8-12h) or buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) may be needed. Antibiotics (e.g., amoxicillin-clavulanate 13.75 mg/kg PO q12h) are indicated for secondary infections. Always adjust dosages for organ dysfunction and monitor for drug interactions.

The literature on oral fibrosarcoma is limited, but several studies provide insights. A retrospective study by Ciekot et al. (1994) evaluated 21 dogs with oral fibrosarcoma and found a median survival time of 9 months, with tumor size and histologic grade being significant prognostic factors. Another study by Forrest et al. (2000) reported that dogs treated with surgery and radiation therapy had a median progression-free interval of 12 months, compared to 4 months with surgery alone. In cats, vaccine-associated sarcomas have been extensively studied; a consensus statement from the Vaccine-Associated Feline Sarcoma Task Force (VAFSTF) recommends aggressive surgical excision with wide margins and consideration of radiation therapy. A study by Kobayashi et al. (2002) found that cats with vaccine-associated sarcomas treated with surgery and radiation had a median survival of 23 months, compared to 6 months with surgery alone. Chemotherapy has shown limited efficacy, but a study by Rassnick et al. (2008) reported a response rate of 20% to doxorubicin in dogs with various sarcomas. Metronomic chemotherapy has been evaluated in a study by Elmslie et al. (2008), showing improved disease-free interval in dogs with hemangiosarcoma, but data in fibrosarcoma is lacking. Overall, the evidence supports aggressive local therapy (surgery and radiation) as the mainstay of treatment, with chemotherapy reserved for metastatic or high-grade disease.